Trial Profile
A Single Dose Pharmacokinetics Study of LY2624803 in Subjects With Hepatic Impairment
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs LY 2624803 (Primary)
- Indications Insomnia
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 02 Jun 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 14 Dec 2010 New trial record